403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx
Follow us:
403 Forbidden

403 Forbidden


nginx

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

August 2, 2007 at 3:37 PM

Federal court thwarts D.C. pharmaceutical price controls

A federal court thwarted the District of Columbia’s efforts to put a lid on medicine prices on constitutional grounds — earning the applause of the biotech industry.

The United States Court of Appeal for the Federal Circuit upheld a lower court’s ruling that found D.C.’s Prescription Drug Excessive Pricing Act of 2005 breached the goals established by patent laws.

The law sought to keep drugs from costing more than 30 percent above what they cost in other developed countries. It also required companies to reveal their invention costs to the authorities.

Supporters said the measure was necessary to counter skyrocketing pharmaceutical costs. Opponents argued that the law would stifle innovation.

The ruling marks a victory for the biotech industry, currently assailed by a legislative effort to pave the way for generics of genetically-engineered therapies.

The Biotechnology Industry Organization commended the court for its decision.

“This law, like other price control measures, would not have had the intended effect of increasing patient access to drugs,” said BIO president Jim Greenwood in a statement.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


403 Forbidden

403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx